Company intelligence / Profile preview

Amphastar Nanjing Pharmaceuticals

Nanjing, Jiangsu, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Amphastar Nanjing produces FDA/GMP-compliant APIs and injectable drugs for a range of indications including diabetes, asthma, Alzheimer's, and cardiovascular conditions. They are a wholly owned active manufacturing and development subsidiary of Amphastar Pharmaceuticals. Clinical programs for proprietary peptide drugs are managed by the parent company through global licensing deals.

Therapeutic areas: CardiovascularOphthalmologyEndocrinologyPulmonologyNeurology
Modalities: Small moleculePeptideEnzymeProtein
Industry: Contract Manufacturing Organization

Partnerships

Nanjing UniversityChina Pharmaceutical UniversityNanjing University of Technology (academic)Amphastar Pharmaceuticals (parent)

Beyond the preview

Go deeper on Amphastar Nanjing Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amphastar Nanjing Pharmaceuticals.

Explore the full profile